CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Capricor Therapeutics, Inc. for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Capricor securities between October 9, 2024, and July 10, 2025 [2]. - The Complaint alleges that Capricor's safety and efficacy data from its Phase 2 HOPE-2 trial was inadequate for regulatory approval, and that the company's public statements regarding regulatory success were overly optimistic [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Capricor have until September 15, 2025, to request appointment as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm that specializes in representing investors in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].